['chronic heart failure']
['rlx030 (serelaxin)', 'placebo']

        Key Inclusion Criteria:

          -  Body weight of ≤ 160 kg.

          -  Subjects with compensated CHF (NYHA Class II - III) at time of screening with a prior
             documented history of chronic heart failure.

          -  NT-proBNP >300 pg/ml (according to central measurement) at visit 1.

          -  Subjects treated with appropriate and guideline-indicated CHF standard of care.

          -  Ability to comply with all requirements, including ability to receive at least a 48
             hour infusion plus follow-up time required for each dosing visit.

        Key Exclusion Criteria:

          -  Current acute decompensated HF

          -  Any major solid organ transplant recipient or planned anticipated organ transplant
             within 1 year.

          -  Documented history of untreated ventricular arrhythmia with syncopal episodes,
             ventricular tachycardia, or ventricular fibrillation without ICD (implantable
             cardioverter defibrillator) with significant hemodynamic consequences within the 3
             months prior to screening.

          -  Presence of hemodynamically significant mitral and /or aortic valve disease, except
             mitral regurgitation secondary to left ventricular dilatation: including significant
             left ventricular outflow obstruction (e.g., obstructive hypertrophic cardiomyopathy,
             severe aortic stenosis)

          -  Subjects with severe renal impairment defined as pre-randomization eGFR < 30
             ml/min/1.73m2 calculated using the sMDRD equation and/or those receiving current or
             planned dialysis or ultrafiltration
      